In addition, Greg Thomas, scientist, SSCI, a division of AMRI, will present "Alcohol-Induced Dose Dumping Studies on Buproprion Hydrochloride Modified Release Tablets," at 12:30 pm, Monday, Nov. 14, on Terminal 33.
"The research we are presenting at AAPS demonstrates AMRI's deep understanding of complex chemistry," stated Christopher Conway, senior vice president of Discovery and Development Services at AMRI. "We are constantly working on innovative ways to solve the problems that arise during drug development and create state-of-the-art methods to help all of our customers get the most robust early stage data on their drug development programs."
AAPS attendees interested in learning more about AMRI's programs can meet with company representatives at Booth 600.
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product, and Fine Chemicals. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amri-to-present-two-posters-at-aaps-2016-300361896.html